 "Under pressure: Chronic therapy needed for an acute condition")
Top pharma companies will continue to face severe pricing pressure and regulatory overhang in FY18. Steps taken to rectify this situation, including launches of complex and niche drugs, will take at least a year to fructify.
Also Read
- Failure to adequately monetise products and higher-than-expected base portfolio price erosion are key worries
- Regulatory overhang given observations by the US FDA for its Goa facility
- In addition to sectoral headwinds, high debt and weak cash flows are other pain points
- Weak Latam, India and other semi-regulated market performance adding to the problems
- Despite strong forecast, the stock, which is down 39 per cent from its peak, will remain under pressure
- Stock is trading at 14 times FY19 earnings estimates and discount to peers unlikely to narrow soon
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%